Male ddY mice, 5 weeks old and weighing 22-24 g, obtained from the Shizuoka Animal Center (Hamamatsu, Japan) were used. They were given standard rodent pellet and water ad libitum and housed at a constant temperature and humidity environment in the university vivarium. Disulfiram was obtained from Tanabe Pharmaceutical Co., Ltd., (Osaka, Japan) in the powder form. The powder was then suspended in 0.8% Tween 80-physiological saline and sonicated for 10 min (Braunsonic).
Ifosfamide was obtained from Shionogi Pharmaceutical Co., Ltd. (Ifomide® for injection, Osaka, Japan). In all studies, ifosfamide was administered intraperitoneally, and disulfiram was adminis tered orally in a volume of 10 ml/kg body weight. The assay of bladder toxicity, based on the drug-induced increase of bladder weight, was essentially similar to that of Brock et al. (1) . Briefly, mice were given various doses of ifosfamide, i.p., and killed by cervical dislocation 48 hr later. The blad ders were excised immediately, blotted and weighed to obtain the relative wet weight to body weight for each animal (mg of bladder weight per 100 g of body weight). To cor relate bladder weight changes with ifosfamide -induced bladder damage , bladders were fixed in 10% neutral phosphate-buffered formalin and prepared for histological study. Determination of statistically significant dif ferences between treatment groups was calculated using Student's t-test. The effect of disulfiram on the urotoxicity of ifosfamide was studied at various dose levels of both the antitumor agent and thiol compound.
Ifosfamide caused a marked increase in bladder weight measured 48 hr after drug administration at 100 mg/kg or higher in a dose-related manner (Fig. 1) . The effect of disulfiram on the ifosfamide induced changes in bladder weight was studied at various dose levels of ifosfamide. When disulfiram was administered simul taneously with ifosfamide by the oral route, as can be seen in Fig. 1 (Fig. 1) . In the subsequent studies, there fore, 200 mg/kg of disulfiram was used. To determine the most effective schedule for the inhibition of ifosfamide-induced increase in bladder weight, disulfiram (200 mg/kg) was administered at various times before or after ifosfamide. These results are shown in Fig. 2 . An oral administration of disulfiram between 60 min before and 60 min after injection of ifosfamide was effective. The protective efficacy of disulfiram was diminished in other periods of time. When administered 120 min before or 120 min after injection of ifosfamide, disulfiram did not protect against the in crease of bladder weight. Bladder weights were normalized to body weight (mg bladder weight per 100 g of body weight).
Each value is presented as the mean (±S.E.) of 8-10 animals. a)values significantly different from the control (P<0 .05). b>sianificantly different from ifosfamide alone (P<0.05). Unlike most other alkylating agents, ifosfamide requires metabolic activation to attain significant cytotoxic and alkylating activity. Indeed, the metabolic products of ifosfamide, including acrolein which is characterized by weak cytotoxic properties, and chloroacetaldehyde have been implicated in this characteristic toxic effect (1, 3), which is a limiting factor in the therapeutic use of the drug, particularly in high-dose chemo therapy regimens.
Because of this dose-limiting toxicity of ifosfamide and related compounds, a great deal of effort has been expended in an at tempt to develop a drug which is as effective as ifosfamide and lacks urotoxic potential. 
